13.09
-0.35(-2.60%)
Currency In USD
| Previous Close | 13.44 |
| Open | 13.38 |
| Day High | 13.38 |
| Day Low | 12.75 |
| 52-Week High | 20.38 |
| 52-Week Low | 5.9 |
| Volume | 692,832 |
| Average Volume | 1.28M |
| Market Cap | 961.04M |
| PE | -16.16 |
| EPS | -0.81 |
| Moving Average 50 Days | 12.5 |
| Moving Average 200 Days | 9.3 |
| Change | -0.35 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $815.58 as of February 12, 2026 at a share price of $13.09. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $161.43 as of February 12, 2026 at a share price of $13.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
GlobeNewswire Inc.
2 hours ago
– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq:
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 06, 2025 1:05 PM GMT
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination approach in diffuse large B-cell lymphoma (DLBCL); initiation expected in 2026 – NEW HAVEN,
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2025 12:00 PM GMT
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Me